… lines (KYSE70, KYSE410, and KYSE450) and two lung cancer cell lines (H1650 and … the
newly synthesized erlotinib derivatives. Three types of esophageal cancer cell lines KYSE70TR…

… -triazole ferrocenyl derivatives of erlotinib together with their anticancer activity studies against
erlotinib-sensitive A549 and H1395 as well as erlotinib-resistant H1650 and H1975 cells. …

… patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau
… Erlotinib (Tarceva™; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative …

… of erlotinib for EGFR is reportedly reduced in H1975 cells … by erlotinib alone was not
notable in A549 and H1975 cells. However, synergism of cytotoxicity between B014 and erlotinib …

… induced apoptosis in a variety of lung cancer cells by downregulating CIP2A and … erlotinib
derivative, TD-19, to demonstrate its potent antitumor efficacy on EGFR wild-type NSCLC cells. …

… Erlotinib derivatives containing 1,2,3-triazole ring were designed and synthesized. Cell-based
assay discovered that PC-9 cells … is still most sensitive to Erlotinib. However, several of the …

… Non–small cell lung cancer (NSCLC) with activating mutations in the epidermal growth …
erlotinib. However, secondary somatic EGFR mutations (eg, T790M) confer resistance to erlotinib…

… Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine … A
prospective Phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p…

… cell lung cancers (NSCLCs). However, intrinsic and acquired resistance to the clinically used
erlotinib … (DC27) in a panel of human lung carcinoma cell lines. The results of a bromodeoxy…

… lung cancers. Quinazoline-based EGFR kinase … of erlotinib derivatives containing 1,2,3-triazole
rings were prepared and evaluated for the antiproliferative activities against HeLa cells. …